IR DEPARTMENT
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO 2023-11-14 08:27
Race Strategic Update August 2023 2023-08-09 07:30
HaemaLogiX and Peter MacCallum Cancer Centre Announce Myeloma CAR-T Phase I Clinical Trial Agreement 2023-07-25 19:30
Race executes agreement with Ardena for GMP manufacturing of RC220 2023-07-13 07:30
Race executes agreement with Ardena for GMP manufacturing of RC220 2023-07-12 19:30
Race executes global license agreement with City of Hope to access FTO IP 2023-07-11 07:30
Race executes global license agreement with City of Hope to access FTO IP 2023-07-10 19:30
HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial 2023-06-29 19:00
EXCELLENT CLINICAL DATA FOR SUBB2M/CA15-3 BREAST CANCER TEST 2023-06-27 19:00
QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION 2023-05-31 19:00
HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR 2023-03-28 09:43
Island to present at World Antiviral Congress 2022 2022-11-15 21:00
US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL 2022-07-25 07:09
HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol 2022-07-08 05:30
Servatus strengthens Board with appointment of biopharmaceutical division head at Boehringer Ingelheim, Dr Uwe Buecheler 2022-05-02 07:36
Project 2025: IR Department's free virtual investor conference is now open for registration 2022-03-28 08:03
Servatus launches Australia's first human study into the effects of live biotherapeutics on insomnia 2022-03-23 05:00
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate 2022-01-28 05:30
XPN Technologies Group Ltd (XPN) lists on the ASX following well supported A$12.5m IPO 2021-12-16 07:17
AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS 2021-12-16 03:58
1 2 3